Italy's National Health Institute (ISS) has recommended that pregnant women should get COVID-19 vaccines after the first three months of their pregnancy, Reuters news agency reported on Friday.
The Italian health authority stated that it was advising women to receive two mRNA-based shots in the second and third trimesters of pregnancy.
According to the ISS, its decision was due to growing evidence on the safety of vaccines during pregnancies for both the foetus and the mother.
Women who are breastfeeding can safely get vaccinated, ISS adding, saying that infants can safely absorb antibodies via milk.
Italy is currently administering two vaccines based on messenger RNA (mRNA) technology, one made by BioNTech (Nasdaq:BNTX) in partnership with Pfizer (NYSE:PFE), and a second from Moderna Inc (Nasdaq:MRNA).
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Yuyu Pharma invests in Dalan Animal Health
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt